A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Recruiting

Phase 3

VX-880A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Sponsor:

Vertex Pharmaceuticals Incorporated

Code:

NCT04786262

Conditions

Diabetes Mellitus, Type 1

Impaired Hypoglycemic Awareness

Severe Hypoglycemia

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

VX-880

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-17. This information was provided to ClinicalTrials.gov by Vertex Pharmaceuticals Incorporated on 2025-03-05.